Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate) and Coluracetam — mechanism, dosing, side effects, legal status, and pricing.
Alpha-GPC is a non-peptide choline-containing phospholipid derivative that serves as an acetylcholine precursor. It is not FDA-approved in the United States, where it is sold as an unregulated dietary supplement and nootropic ingredient. The compound is marketed as a prescription drug in some countries (e.g., Italy as Gliatilin) for cognitive and vascular disorders, though current regulatory approval status has not been confirmed against primary agency databases. Alpha-GPC is not identified as a WADA-prohibited substance in secondary sources.
Coluracetam is a non-peptide small-molecule racetam-family nootropic (pyrrolidinone-substituted tetrahydrofuroquinoline) that enhances high-affinity choline uptake (HACU), the rate-limiting step in acetylcholine synthesis. Originally developed by Mitsubishi Tanabe Pharma as MKC-231 for Alzheimer's disease and later by BrainCells Inc. as BCI-540 for major depressive disorder, it is not FDA-approved for any indication and remains inactive in U.S. regulatory development. Sold only as an unregulated research chemical/nootropic powder with no validated human dose or safety profile.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
Coluracetam
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
Coluracetam
COA corpus from Disclosed Labs — independently tested batches only.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
No COA data yet.
Submit testing data →Coluracetam
2
COAs
99.7%
Avg purity
2
Labs
Human data: A 12-week randomized controlled trial in 100 subjects with amnestic mild cognitive impairment found 600 mg/day improved ADAS-cog scores by 2.34 points versus placebo with no serious adverse events. A single-blind RCT in 39 healthy volunteers showed 400 mg/day for 2 weeks increased self-reported motivation versus placebo. A small crossover study in 7 resistance-trained men (published only as a conference-supplement abstract) reported a single acute 600 mg dose increased post-exercise growth hormone and peak bench-press force versus placebo. A large retrospective Korean cohort study (n=12,008,977 adults ≥50) found chronic alpha-GPC use associated with elevated 10-year stroke risk (total stroke adjusted HR 1.43, ischemic stroke aHR 1.34) in a dose-dependent pattern. Preclinical: Rat studies showed increased hippocampal acetylcholine release, modulation of choline acetyltransferase/acetylcholinesterase activity in aged rats, attenuation of age-related brain structural changes, and increased hippocampal neurogenesis in seizure models.
Key references
No peer-reviewed or regulatory-posted human efficacy or safety data exist. One Phase 2 randomized, double-blind, placebo-controlled trial (NCT00621270) tested BCI-540 (80 mg once daily or three times daily vs. placebo) in 115 participants with major depressive disorder and concomitant anxiety (Jan 2008–Oct 2009); the trial is listed as Completed but has no results posted (hasResults=false, confirmed via ClinicalTrials.gov). In rodent models, oral coluracetam (1–10 mg/kg) significantly improved Morris water-maze learning deficits in AF64A-lesioned rats without tremor, salivation, or hypothermia, and reversed working-memory deficits and hippocampal acetylcholine depletion in AF64A-treated mice (Bessho et al. 1996, PMID 8740080; Murai et al. 1994, PMID 7710736). Coluracetam is not FDA-approved for any indication; U.S. development for Alzheimer's disease is listed as Inactive.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate) and Coluracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Key references
Disclosed Labs